Kiechle M - Search Results

1

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.

Absmaier M, Napieralski R, Schuster T, Aubele M, Walch A, Magdolen V, Dorn J, Gross E, Harbeck N, Noske A, Kiechle M, Schmitt M. Absmaier M, et al. Among authors: kiechle m. Int J Oncol. 2018 Mar;52(3):755-767. doi: 10.3892/ijo.2018.4241. Epub 2018 Jan 8. Int J Oncol. 2018. PMID: 29328369 Free PMC article.

2

A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC.

Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M. Gross E, et al. Among authors: kiechle m. Hum Genet. 1999 Jul-Aug;105(1-2):72-8. doi: 10.1007/s004399900092. Hum Genet. 1999. PMID: 10480358

3

A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers.

Arnold N, Gross E, Schwarz-Boeger U, Pfisterer J, Jonat W, Kiechle M. Arnold N, et al. Among authors: kiechle m. Hum Mutat. 1999;14(4):333-9. doi: 10.1002/(SICI)1098-1004(199910)14:4<333::AID-HUMU9>3.0.CO;2-C. Hum Mutat. 1999. PMID: 10502781

4

Identification of specific BRCA1 and BRCA2 variants by DHPLC.

Gross E, Arnold N, Pfeifer K, Bandick K, Kiechle M. Gross E, et al. Among authors: kiechle m. Hum Mutat. 2000 Oct;16(4):345-53. doi: 10.1002/1098-1004(200010)16:4<345::AID-HUMU7>3.0.CO;2-#. Hum Mutat. 2000. PMID: 11013445

5

Mutation analysis of p53 in ovarian tumors by DHPLC.

Gross E, Kiechle M, Arnold N. Gross E, et al. Among authors: kiechle m. J Biochem Biophys Methods. 2001 Jan 30;47(1-2):73-81. doi: 10.1016/s0165-022x(00)00153-6. J Biochem Biophys Methods. 2001. PMID: 11179763

6

[Breast carcinoma. Biological principles, classification and prognostic factors].

Braun S, Kiechle M, Harbeck N. Braun S, et al. Among authors: kiechle m. Internist (Berl). 2002 Mar;43(3):329-30, 333-9. doi: 10.1007/s00108-001-0522-4. Internist (Berl). 2002. PMID: 11963718 Review. German. No abstract available.

7

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Harbeck N, et al. Among authors: kiechle m. Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417

8

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Among authors: kiechle m. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

9

High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.

Gross E, Seck K, Neubauer S, Mayr J, Hellebrand H, Ratanaphan A, Lutz V, Stockinger H, Kiechle M. Gross E, et al. Among authors: kiechle m. Int J Oncol. 2003 Feb;22(2):325-32. Int J Oncol. 2003. PMID: 12527930

10

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Zemzoum I, et al. Among authors: kiechle m. J Clin Oncol. 2003 Mar 15;21(6):1022-8. doi: 10.1200/JCO.2003.04.170. J Clin Oncol. 2003. PMID: 12637466

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

300 results

Search Page

Filters